Ms. Sears most recently served as SVP & Interim CHRO at Allergan and will have responsibility for all aspects of AskBio’s human capital management.
Category: News
AskBio Awarded £2m Scottish Enterprise R&D Grant to Help Reduce Barriers to Mainstream Gene Therapy
This grant has been awarded to AskBio Europe (formerly Synpromics) to develop solutions to industry-wide challenges and creates 11 new, high-value jobs in Edinburgh.
AskBio CSO Jude Samulski Receives 2020 Life Sciences Award from the Triangle Business Journal
As one of only four individuals awarded in 2020, Dr. Samulski is featured alongside this year’s class of 11 winners.
AskBio Named to Inc. 5000 List of Fastest-Growing Private Companies
AskBio ranked No. 652 by Inc. magazine on its annual Inc. 5000 list of the fastest-growing privately held companies.
AskBio Appoints Michael Kranda as SVP Therapeutic Practice Leader for Its Growing CNS Portfolio
Kranda comes to AskBio from the Allen Institute, where, since 2016, he served as senior director of business development.
AskBio CSO Jude Samulski Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
Dr. Samulski is recognized in the Entrepreneurs category as a transformative leader in genetic medicine.
Libbie Mansell Joins AskBio as SVP Regulatory Affairs
Dr. Mansell’s 30-year career has spanned development of small molecules and biologics, resulting in nine successful approvals.
AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing System
Technology brings together benefits of AAV and CRISPR while minimizing negative effects that occur during gene editing.
AskBio Appoints Tim Trost as Chief Financial Officer
Trost is a highly accomplished CFO with more than 25 years of experience building, managing and financing emerging life sciences companies.
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
Acquisition adds Huntington’s disease gene therapy candidate to AskBio’s clinical program and provides access to pipeline for additional indications.
